| Sep 3 |
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Candel Therapeutics GAAP EPS of -$0.74
|
| Aug 13 |
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Jul 1 |
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
|
| Jun 18 |
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
|
| Jun 14 |
Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
|
| Jun 14 |
7 A-Rated Biotech Stocks Worth Betting on in June
|
| Jun 11 |
Candel Therapeutics to join Russell 3000 Index
|
| Jun 11 |
Candel Therapeutics to Join Russell 3000® Index
|
| Jun 3 |
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
|
